Public Profile

Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for genetically defined diseases. Founded in 2016, Fulcrum has made significant strides in the industry, particularly in the field of rare genetic disorders. The company is renowned for its unique approach to drug development, leveraging its proprietary gene modulation platform to create targeted treatments. Fulcrum's lead product candidates aim to address unmet medical needs, setting the company apart in a competitive market. With a commitment to advancing science and improving patient outcomes, Fulcrum Therapeutics has established itself as a key player in the biopharmaceutical landscape, continually striving for excellence in the pursuit of transformative therapies.

DitchCarbon Score

How does Fulcrum Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

18

Industry Average

Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

19

Industry Benchmark

Fulcrum Therapeutics, Inc.'s score of 18 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.

23%

Let us know if this data was useful to you

Fulcrum Therapeutics, Inc.'s reported carbon emissions

Fulcrum Therapeutics, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. As such, there are no reported figures for their Scope 1, 2, or 3 emissions. The company has not outlined any formal climate commitments or initiatives aimed at reducing carbon emissions. In the absence of specific data, it is essential to monitor their future sustainability efforts and commitments within the biopharmaceutical industry, which increasingly prioritises environmental responsibility.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Fulcrum Therapeutics, Inc.'s primary industry is Health and social work services (85), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Fulcrum Therapeutics, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Fulcrum Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Moderna

US
Medical, precision and optical instruments, watches and clocks (33)
Updated 16 days ago

Alnylam Pharmaceuticals

US
Medical, precision and optical instruments, watches and clocks (33)
Updated 22 days ago

Wave Life Sciences Ltd.

SG
Health and social work services (85)
Updated 22 days ago

Roche Innovation Center Copenhagen A/S

DK
Research and development services (73)
Updated 4 months ago
DitchCarbon Score

Avidity, LLC

US
Updated 22 days ago

ABUS

DE
Fabricated metal products, except machinery and equipment (28)
Updated 22 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers